IRIX Iridex Corp.

Iridex to Participate in Fireside Chat with Stifel Equity Research

Iridex to Participate in Fireside Chat with Stifel Equity Research

MOUNTAIN VIEW, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company plans to participate in a fireside chat with its covering equity research analyst from Stifel.

Management is scheduled to discuss the business on Thursday, December 8, 2022 at 9:00 a.m. PT / 12:00 p.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: .

About Iridex

Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit .

Investor Relations Contact:

Philip Taylor

(415) 937-5406



EN
06/12/2022

Underlying

IRIXIridex Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Iridex Corp.

 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces Plans to Relocate Headquarters

Iridex Announces Plans to Relocate Headquarters Move expected to generate significant cost savings MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company’s headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease (the “Lease”). The...

February 2, 2026 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces Preliminary Operational and Financial Results for Fou...

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourt...

January 12, 2026 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces the Publication of an Independent Study Demonstrating...

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of tra...

December 11, 2025 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical ...

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments f...

December 8, 2025 1 EN
 PRESS RELEASE
Free
IRIX IRIDEX CORP.

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Iridex to Present at the Sidoti Year-End Virtual Investor Conference MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Sidoti Year-End Virtual Investor Conference. Management is scheduled to present on Thursday, December 11 at 10:45 am ET. Interested parties may access a live and archived webcast of the presentation on the “Even...

December 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch